Cardiovascular Risk Factors
Use of low-dose OCs increases risk of cardiac and vascular events
Published in Women's Health Weekly, September 8th, 2005
According to recent research published in the The Journal of Clinical Endocrinology and Metabolism, "The long-term cardiovascular safety of widely used oral contraceptives (OCs) is still debated, and no meta-analysis assesses the modern use of OCs and the associated cardiovascular risks. We aimed to assess the risk of cardiovascular diseases associated with current use of low-dose combined OCs."
J.P. Baillargeon and colleagues of the University of Sherbrooke explained, "All studies published between January...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
CD44 attenuated metastatic invasion during breast cancer progression - Hormones
Epithelial cell T-bet expression studied, role of female steroid hormones shown - Medical Devices
Preclinical studies of anti-adhesion thermal gel in gynecologic surgery underway - Osteoporosis
Companies announce agreement to develop new drug targeting osteoporosis - Antiproliferative Activity
Lamprey gonadotropin-releasing hormone III inhibited breast cancer cell growth - Bacterial Vaginosis
To understand BV, more research is needed on vaginal flora, related issues - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
